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Abstract
Background: We aimed to investigate the function of miR-1307 in chemoresistance and to explore its
chemoresistance mechanism in ovarian cancer.
Methods: IC50 determination was used to test the chemoresistance profling in ovarian cancer cells. QRT-PCR or
western blot was used to validate the expression level of miR-1307 and candidate gene or protein. Colony
formation assay and FITC-labeled enhanced Annexin V immunofluorescence were used to compare cell
proliferation and apoptosis ability, respectively. The potential target gene and its biological function of miRNA-1307
were also analyzed. Bioinformatics and Luciferase Reporter Gene Assay were conducted to validate the regulation
of miRNA-1307 on the ING5 expression. Xenografts assay was used to demonstrate the inhibiting effect of miR-1307
ASO and Taxol therapy against ovarian cancer in vivo.
Results: MiR-1307 was over-expressed in chemoresistant ovarian cancer cell line A2780/Taxol, and over-expression
or loss of miR-1307 promoted or inhabited chemoresistance. And we also found that the over-expression of miR-
1307 promoted proliferation and inhibited apoptosis in ovarian cancer cells. Besides, we demonstrated that ING5
was a direct target of miR-1307 and miR-1307 down-regulated the ING5 expression in ovarian cancer cells.
Additionally, we showed that ING5 inhibited cell proliferation, promoted cell apoptosis and inhabited
chemoresistance reversely. Furthermore, the up-regulated ability of cell apoptosis and down-regulated ability of
chemoresistance following the loss of miR-1307 was reversed by adding ING5 siRNA in vitro. Finally, we proved
the inhibiting effect of miR-1307 ASO and Taxol therapy by increasing the ING5 expression against ovarian cancer
through xenografts assay in vivo.
Conclusion: Our results suggested that miR-1307 could promote ovarian cancer chemoresistance by targeting the
ING5 expression and miR-1307 might serve as a therapeutic target for ovarian cancer.
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Background
Ovarian cancer is a malignancy with with the fifth mortal-
ity in female malignant tumors and the highest mortality
rate in gynecological cancers, of which epithelial ovarian
carcinoma (EOC) is the most common pathologic type
accounting for 85–90%. It is estimated that there will be
22,280 Americans diagnosed with ovarian cancer in 2016,
and 14,240 of them will die from the disease [1]. The high
mortality rate of ovarian cancer is associated with the
difficulties of early detection, because most patients are
not diagnosed until late stage (stage III or IV) in their
disease [2]. Besides, for the patients of ovarian cancer, the
majority experience relapse within 2 years [3]. Chemother-
apy plays an important role in the therapy for ovarian
cancer, but chemoresistance during chemotherapy makes
treatment particularly challenging. The chemoresistance
has been one of the main reasons for the high mortality of
ovarian cancer [4]. Therefore, it is urgent to discover
new treatment strategies for reducing the occurrence of
chemoresistance to help improve prognosis.* Correspondence: bingyang810@163.com
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As a class of small non-coding RNA molecules,
miRNAs are endogenously expressed, single-stranded
and 19–25 nucleotides long [2, 5, 6]. MiRNAs, as
transcriptional repressors, regulate gene expression
by directly binding the 3’ untranslated region of their
target miRNAs [2, 5, 6]. Numerous studies had
proved that miRNAs are involved in regulation of al-
most all cellular processes including proliferation and
apoptosis [2, 5–7]. Recently, miRNAs have been re-
ported to either promote carcinogenesis by inhibiting
tumor suppressors or suppress tumor development
by acting as down-regulate oncogenes in ovarian can-
cer: downregulated miRNAs (including let-7a/b/d/f,
miR-31, 34abc, 92a, 99b, 125b, 127, 152, 155 and 199a),
and over-expressed oncogenic miRNAs (such as miR-
18a, 20a, 21, 23a/b, 29a, 92, 93, 126, 141, 199a-3p,
200b/c and 429) [2, 8–12]. Moreover, about 27 dysregu-
lated miRNAs have been linked to chemo-resistance to
taxanes or platinum compounds in ovarian cancer [13].
Over-expression of miR-27a and miR-514 or loss of let-
7i/let-7e have been related to resistance to taxanes and/
or platinum [13, 14]. MiR-93 and MiR-214 can promote
cisplatin resistance by targeting PTEN/AKT [9, 15].
MiR-376c can promote cisplatin resistance by targeting
ALK7 [9]. MiR-214 can promote paclitaxel resistance
by targeting BCL10 and caspase-7, and miR-433 or
miR-182 can promote paclitaxel resistance by targeting
MAD2 or PDCD4 [9]. MiR-141 can promote platinum
resistance by targeting KEAP1 [9]. Two studies have
reported that miRNA is involved in the development of
chemoresistance in ovarian cancer by inhibiting pro-
apoptotic signal pathway [4, 8]. Additionally, up-
regulation of miR-300 can inhibit cellular apoptosis
through TGF-β, resulting in chemoresistance enhance-
ment in ovarian cancer cells [16]. Particularly, it has
been reported that miRNA-1307 is over-expressed in
chemoresistant ovarian cancer tissues compared to the
chemosensitive counterparts, indicating that miR-1307
is associated with the chemoresistance in ovarian
cancer [7]. However, up to now, the functional study of
miR-1307 has been limited, and the chemoresistance
mechanism of miR-1307 in ovarian cancer is still
unclear.
In the present study, we evaluated the miR-1307 ex-
pression in chemoresistant ovarian cancer cell line
A2780/Taxol and the function of miR-1307 for chemore-
sistance in various kinds of ovarian cancer cells. We also
performed a systematic analysis on miR-1307 for its role
in ovarian cancer chemoresistance and a preliminary
analysis on the mechanism. Finally, our results indicated
miR-1307 could promote ovarian cancer chemoresis-
tance by reducing the ING5 expression in vitro and in




Human ovarian cancer cell line A2780, SKOV3 and
paclitaxel-resistant A2780 (A2780/Taxol) were obtained
from the the Committee of Type Culture Collection of
the Chinese Academy of Sciences (Shanghai, China).
The SKOV3 and A2780/Taxol cells were maintained in
RPMI-1640 medium, while the A2780 cellswere main-
tained in Dulbecco’s modified Eagle’s medium (DMEM).
Ten percent fetal bovine serum (FBS), 100 units · mL−1
penicillin and 100 μg · mL−1 streptomycin were added in
the above. All cells were incubated at 37 °C in a humidi-
fied atmosphere of 95% air and 5% CO2.
Chemoresistance profling (IC50 determination) [17, 18]
Cells were seeded in triplicate in 96-well plates at the
density of 5 × 103/well and treated differently or not
in the various kinds of ovarian cancer cells for 72 h.
Cell survival was then measured by a thiazolyl blue
tetrazolium bromide (MTT, 490 nm reading)-based
cell proliferation assay. Both the linear regression
parameters and the IC50 (the concentration of drug
required for 50% of cells to be killed) with the no-
drug control as the reference were calculated. The
relative chemoresistance was presented as the fold for
each of the cell line over the lowest IC50.
RNA analysis
Total RNA was isolated from the cells at the logarith-
mic phase using TRIzol reagent (Tiangen Biotech Co.,
Ltd., Beijing, China). For mRNA analysis, cDNA primed
by oligo-dT was generated using a PrimeScript RT
reagent kit (Tiangen Biotech Co., Ltd., Beijing, China),
and the mRNA levels of the genes were quantifed by
duplex-QRT-PCR analysis using TaqMan probes with a
different fuorescence for the β-actin (provided by Shing
Gene, Shanghai, China) and a FTC-3000P PCR instru-
ment (Funglyn Biotech Inc, Canada). PCR cycle condi-
tions are: 95 °C for 5 min, followed by 40 cycles of 95 °C
10s, 60 °C 20s, 72 °C 20s, and 78 °C 20s. Using the 2-
ΔΔCt method, gene expression was normalized to β-actin
and then compared between groups. The sequences of the
primers and probes used for the QRT-PCR analysis were
as follows:
miR-1307 F: 5’-AACTCGGCGTGGC -3’,
miR-1307 R: 5’-GAGCAGGCTGGAGAA-3’.
U6 was used as internal control in RT-PCR:
U6 F: 5’-GCTTCGGCAGCACATATACTAAAAT-3’,
U6 R: 5’-CGCTTCACGAATTTGCGTGTCAT-3’.
ING5 F: 5’- TCCAGAACGCCTACAGCAAG -3’,
ING5 R: 5’- TGCCCTCCATCTTGTCCTTC -3’,
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ING5 probe: 5’- CY5-CGACAAAGTGCAGCTG
GCCATGC -3’.
Experiment was performed independently for three
times.
Reagents for the transient transfection assays
The miR-1307 mimics, miR-1307 ASO, siRNA and the
scramble sequence control were supplied by Guangzhou
Ribobio (Guangzhou, China). The transfection was used
by Lipofectamine-2000 in accordance with the manufac-
turer’s guidelines (Invitrogen). The final concentration of
antisense oligodeoxynucleotide (ASO) con and miR-1307
ASO was 100 nM. Untreated cells were designated as the
blank control group.
The siRNA sequences used for ING5 interference in




Cell proliferation ability was compared by colony forma-
tion assays. 6-well plates were used to seed cell suspen-
sions, 300 cells per well. After incubated, cells were fixed
in methyl hydrate for 10 min. Then the colonies were
stained and they were counted by using an optical
microscope.
Western blot
A quantity of 30 ug of lysates per sample was separated
by SDS–PAGE using 10% polyacrylamide gels and
transferred to PVDF membrane which was subse-
quently incubated with the antibody (see the below) for
4 °C overnight, and corresponding were immunode-
tected by incubation with HRP (horseradish peroxid-
ase)-linked related secondary antibody using an ECL
detection kit (Pierce Biotechnology). The antibodies
used in this article were below: rabbit monoclonal Ki67
antibody (sc-15,402, 1:1000 dilution), mouse monoclo-
nal PCNA antibody (sc-25,280, 1:1000 dilution), mouse
monoclonal caspase-3 antibody (sc-65,496, 1:1000 dilu-
tion), mouse monoclonal caspase-7 antibody (sc-81,655,
1:1000 dilution), rabbit monoclonal ING5 antibody
(10665-1-AP, 1:1000 dilution), mouse monoclonal β-
actin antibody (sc-8432, 1:2500 dilution), the secondary
antibodies preparation was either anti-rabbit (1:5000)
or anti-mouse (1:5000).
Apoptosis analysis by FITC immunofluorescence
Cells were harvested and rinsed with phosphate-buffered
saline (PBS) twice. Then, 5 μl of fuorescein isothiocyanate
(FITC)-labeled enhanced Annexin V and 5 μl (20 μg/ml)
of propidium iodide were added to the 100 μl cell suspen-
sion. Following incubation in the dark for 15 min at room
temperature, the samples were diluted with 400 μl PBS.
Then dropped the cell suspension on the slide after dye-
ing, and covered it with a cover glass cell for detection by
using fluorescence microscope. Annexin V-FITC showed
the green fluorescence, and DAPI showed the blue fluor-
escence. The results were analyzed according to the man-
ufacturer’s instructions. The experiments were performed
independently three times, and a representative result was
shown herein.
Analysis of miRNA target genes and gene ontology analysis
Target Scan, miRanda and Diana microT-CDS were used
to analyze the potential target genes for miR-1307. GOstat
was used for gene enrichment analysis. The DAVID
database was used for signal transduction enrichment
Analysis.
Dual-luciferase reporter assay [19]
5 × 104 cells per well in 12-well plates were cultured with-
out antibiotics overnight and then transfected with cloned
ING5 wild-type 3’-UTR target sequence and mutant 3’-
UTR by using Lipofectamine 2000 (Invitrogen). After
48 h, cells were washed with PBS, subjected to lysis, and
their luciferase activities measured by using a dual lucifer-
ase assay kit (Promega). The results were normalized
against Renella Luciferase. Each reporter plasmid was
transfected at least three times. The wild sequence for
ING5: 3’ UTR: AGCUGGCCCUCGACGCCCGGACC,
while mutant sequence was 3’UTR: ACCAGCCGCUC
GACGCCCGGACC. Both of them were designed and
purchased from Shanghai Genechem Co., Ltd (Shanghai,
China).
Xenografts assays in vivo
The animal study was carried out in accordance with the
guidelines approved by the Animal Experimentation
Ethics Committee of affiliated hospital of Zunyi medical
college. The protocol was approved by the committee,
all surgery was performed under sodium pentobarbital
anesthesia, and all efforts were made to minimize suffer-
ing. Athymic Balb/c nude mice (aged 5 weeks) were pro-
vided by Slac Laboratory Animal Co. Ltd. (Shanghai,
China), and the mice were housed in a pathogen-free
animal facility and randomly assigned to the control or
experimental group (six mice per group) [20]. 2 × 106
A2780 cells were suspended in 0.1 mL of serum-free
RPMI 1640 was injected into the right subaxillary of
each mouse [20]. And the mice were divided into 5
groups which were treated differently on the day 14 (the
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tumor volume reached about 50–100 mm3): The mice
were injected with MOCK (transfected with vector),
Taxol, ASO con, miR-1307 ASO, or miR-1307 ASO +
Taxol once every 2 days (8 times in all) [17]. The final
concentration of MOCK, ASO con and miR-1307 ASO
was 100 nM intratumorally injected into A2780 cells every
time, respectively (0.01 mol). And taxol was injected
10 mg/kg for the mice intraperitoneally. The tumors were
measured by vernier caliper on the day 14, 17, 21, 23, 26,
and 29. The following formula was used for calculation of
tumor volume: Tumor volume (mm3) = tumor length
(mm) × tumor width (mm) × tumor width (mm)/2. 29 days
after inoculation, mice were killed, and the final volume of
tumor tissues was determined.
Statistical analysis
The experiments’ results in vitro and in vivo were
depicted as mean ± SD. Student’s two-sided t-test was
used to compare values of test and control samples. All
calculations were performed with the SPSS 18.0 and the
level of significance was set to P < 0.05.
Results
MiR-1307 was over-expressed in chemoresistant ovarian
cancer cell line A2780/taxol, and over-expression or loss
of miR-1307 promoted or inhabited chemoresistance
To prove the characteristics of chemoresistant ovarian
cancer cells, we showed the IC50 difference between
the A2780 and A2780/Taxol cells: IC50 in the chemore-
sistant A2780/Taxol cells was much bigger than that in
the A2780 cells (P < 0.01, Fig. 1a). To determine if miR-
1307 had a role in chemoresistant ovarian cancer cells,
we performed QRT-PCR to detect the miR-1307 ex-
pression in the A2780 and A2780/Taxol cells. Our re-
sults indicated that miR-1307 was over-expressed in
chemoresistant ovarian cancer cell A2780/Taxol, and
perhaps miR-1307 promoted cell chemoresistance in
cell A2780/Taxol compared to cell A2780 (P < 0.01,
Fig. 1a). To further investigate the apoptosis effect of
miR-1307 in ovarian cancer cells, we transferred miR-
1307 mimics or ASO to increase or decrease miR-1307
expression both into the A2780 or SKOV3 cells. The
results of IC50 determination revealed that increased
Fig. 1 The over-expression and function of miR-1307 in chemoresistant ovarian cancer cells. a Chemoresistance of A2780 and A2780/Taxol cells.
The relative cell survival rates over mock treatment was calculated and plotted. Diagram line about different concentrations of drugs and inhibition
rate, the IC50 difference between A2780 and A2780/Taxol cells and the miR-1307 expression were shown (the same below). The IC50 and the relative
fold were presented in table (the same below). The IC50 in the chemoresistant A2780/Taxol cells was much bigger than that in the A2780 cells
(P < 0.01). QRT-PCR results indicated miR-1307 was over-expressed in A2780/Taxol cells compared to A2780 cells (P < 0.01). b Chemoresistance
of miR-1307 mimics transfection and control group in the A2780 or SKOV3 cells. The results of IC50 determination revealed that the IC50 was
bigger in the miR-1307 mimics group than that in the miRNA control group in the A2780 or SKOV3 cells (P < 0.01, respectively). c Chemoresistance
of miR-1307 ASO transfection and control group in the A2780 or SKOV3 cells. The results of IC50 determination revealed that the IC50 was smaller in
the miR-1307 ASO group than that in the ASO control group in the A2780 or SKOV3 cells (P < 0.01, respectively). d Chemoresistance of miR-1307 ASO
transfection and control group in the A2780/Taxol cells. And the results of IC50 determination revealed that the IC50 was smaller than that in the ASO
control group in the A2780/Taxol cells (P < 0.01). At least three independent experiments were conducted. Data from three experimental
determinations and bars indicate the SD. Data are expressed as the mean ± standard deviation (** P < 0.01)
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or decreased miR-1307 expression could promote or
inhibit chemoresistance (IC50 bigger or smaller than
the control, P < 0.01, respectively, Fig. 1b and c). To
demonstrate the therapy effect on the chemoresistant
ovarian cancer cells, we transferred miR-1307 ASO into
the A2780/Taxol cells. And the results of IC50 deter-
mination revealed that decreased miR-1307 expression
could inhabit chemoresistance (IC50 smaller than the
control, P < 0.01, Fig. 1d).
To sum up, these results indicated that miR-1307 was
over-expressed in chemoresistant ovarian cancer cell line
A2780/Taxol, and miR-1307 promoted chemoresistance.
Over-expression of miR-1307 inhibited cell apoptosis and
promoted cell proliferation in ovarian cancer cells
Moreover, to performe a systematic analysis on miR-
1307 for its role in ovarian cancer chemoresistance,
we transferred miR-1307 mimics into three ovarian
cancer cells (A2780, SKOV3 and A2780/Taxol) and
analyzed the effect on the proliferation and apoptosis
compared to the control. The results of colony forma-
tion assay showed that capacity for colony formation
was significantly enhanced in miR-1307 mimics trans-
fection cells compared to control (P < 0.05, respect-
ively, Fig. 2a). Besides, the results of annexin V-FITC
immunofluorescence assay showed significantly more
cells of FITC in miR-1307 mimics transfection cells
compared to control (P < 0.05, respectively, Fig. 2b).
Additionally, to prove the above results and analyze
the mechanism of apoptosis, we used western blot
method to detect the protein of caspase-3 and
caspase-7, which were used to be genetic markers of
apoptosis. As shown in Fig. 2c, the expression level of
protein caspase-3 and caspase-7 in miR-1307 mimics
transfection cells was higher than that in the controls,
respectively (P < 0.05).
In a word, these results indicated that over-expression
of miR-1307, which was associated with chemoresis-
tance, inhibited cell apoptosis and promoted cell prolif-
eration in ovarian cancer cells.
ING5 was a direct target of miR-1307 and miR-1307 down-
regulated the ING5 expression in ovarian cancer cells
To identify the downstream target genes of the miR-
1307, we performed chip analysis and found that ING5
is a target gene of miR-1307 (unpublished data, not
shown). Incidentally, ING5 was on the list of miR-1307
targets suggested by Target Scan software (http://
www.targetscan.org/). In addition, to demonstrate the
regulatory effect on miR-1307 and downstream gene
Fig. 2 Influence of miR-1307 on the biological behaviors of ovarian cancer cell lines. MiR-1307 mimics or control was transferred into three
ovarian cancer cells (A2780, SKOV3 and A2780/Taxol). a Colony formation. Cells were cultured in 6-well plates and analyzed by colony formation assay.
After 10 days, cells were stained, photographed (left) and counted (right). The results of colony formation assay showed that capacity for colony
formation was significantly enhanced in miR-1307 mimics transfection cells compared to control in the A2780 or SKOV3 cells (P < 0.05,
respectively). b The results of annexin V-FITC immunofluorescence assay. Cells were stained, photographed (left) and counted (right). The results of
annexin V-FITC immunofluorescence assay showed significantly more cells of FITC in miR-1307 mimics transfection cells compared to control in the
A2780 or SKOV3 cells (P < 0.05, respectively). c The expression level of protein caspase-3 and caspase-7 by using western blot in different groups. The
expression level of protein caspase-3 or caspase-7 in miR-1307 mimics transfection cells was higher than that in the control in the A2780 or SKOV3 cells
(P < 0.05, respectively). At least three independent experiments were conducted. Data from three experimental determinations and bars indicate the
SD. Data are expressed as the mean ± standard deviation (* P < 0.05)
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ING5, we inserted the ING5 UTR (1–1037 bp) with either
a wild-type or mutant miR-1307 target sequence down-
stream of the firefly lucierase gene into the pGL3-control
vector (Promega) to create the pGL3-ING5 UTR WT or
the pGL3-ING5 UTR Mut construct, respectively (Fig. 3a).
The pGL3-ING5 UTR WT, pGL3-ING5 UTR Mut and
pGL3 constructs were individually transfected into A2780
cells. Then we performed luciferase reporter assays with
the wild-type or mutant 3’UTR of miR-1307. Our results
demonstrated that miR-1307 significantly decreased the
relative (A1/A2: pGL3-ING5 UTR WT or pGL3-ING5
UTR Mut construct group / pGL3 construct group) lucif-
erase activity of the wild-type miR-1307 3’UTR compared
to the mutant miR-1307 3’UTR, indicating that miR-
1307 might directly bind to the 3’UTR of ING5 (Fig. 3b,
P < 0.05). In conclusion, the ING5 gene is a direct post-
transcriptional target of miR-1307.
To further validate the relationship between miR-1307
and ING5 in ovarian cancer cells, we detected the level
of ING5 protein expression following different miR-1307
treatment in various kinds of ovarian cancer cells by
western blot. The results showed the ING5 protein ex-
pression level was lower in A2780/Taxol cells than that
in A2780 cells (Fig. 3c, P < 0.05). From the above results
(Fig. 1a), we knew that the miR-1307 expression level
was lower in A2780/Taxol cells than that in A2780 cells
(P < 0.01). Moreover, our results showed the ING5 pro-
tein expression level was lower treated with miR-1307
mimics than that treated with miRNA con in the A2780
or SKOV3 cells, respectively (Fig. 3d, P < 0.01). Further-
more, our results showed the ING5 protein expression
level was higher treated with miR-1307 ASO than that
treated with ASO con in the A2780 or SKOV3 cells,
respectively (Fig. 3d, P < 0.05). That was to say, over-
expression or loss of miR-1307 could down- or up-
regulated the expression level of protein ING5. Taken
together, miR-1307 could down-regulate the ING5 ex-
pression in ovarian cancer cells.
Fig. 3 MiR-1307 down-regulated the direct target ING5 expression in vitro. a Bioinformatics results. The 3’-untranslated region (3’-UTR) of ING5
contains a potential miRNA-binding site for miR-1307. We inserted the ING5 UTR (1–1037 bp) with either a wild-type or mutant miR-1307 target
sequence downstream of the firefly lucierase gene into the pGL3-control vector (Promega) to create the pGL3-ING5 UTR WT or the pGL3-ING5
UTR Mut construct, respectively. b Luciferase reporter assay results. The pGL3-ING5 UTR WT, pGL3-ING5 UTR Mut and pGL3 constructs were
individually transfected into A2780 cells. MiR-1307 significantly decreased the relative luciferase activity of the wild-type ING5 3’UTR compared
with the mutant ING5 3’UTR. c The ING5 protein expression level following different miR-1307 treatment in A2780/Taxol and A2780 cells by using
western blot. The results showed the ING5 protein expression level was lower in A2780/Taxol cells than that in A2780 cells (P < 0.05). d The ING5
protein expression level following different miR-1307 treatment in ovarian cancer cells by using western blot. The ING5 protein expression level
was lower treated with miR-1307 mimics than that treated with miRNA con in the A2780 or SKOV3 cells (P < 0.05, respectively). Moreover, the
ING5 protein expression level was higher treated with miR-1307 ASO than that treated with ASO con in the A2780 or SKOV3 cells (P < 0.05,
respectively). Results are representative of at least three separate experiments. Data are expressed as the mean ± standard deviation. Data from
three experimental determinations and bars indicate the SD (*P < 0.05, **P < 0.01)
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The loss of ING5 expression promoted cell proliferation,
inhibited cell apoptosis, and promoted chemoresistance
in ovarian cancer cells
To investigate the influence of ING5 on the biological
behaviors of ovarian cancer cells, ING5 siRNA was
used to reduce the expression of ING5 in A2780 and
SKOV3 cells: as shown in Fig. 4a, the expression of
ING5 in A2780 or SKOV3 cells was reduced, respect-
ively (P < 0.01). The results of colony formation assay
or annexin V-FITC immunofluorescence assay showed
that capacity for colony formation was significantly en-
hanced compared to the control in A2780 or SKOV3 cells,
respectively (P < 0.05, Fig. 4b). The results of annexin V-
FITC immunofluorescence assay or IC50 showed that sig-
nificantly more cells of FITC or bigger IC50 compared
with control in A2780 or SKOV3 cells (P < 0.05, respect-
ively, Fig. 4c and d). As a whole, the results indicated that
loss of ING5 expression promoted cell proliferation, inhib-
ited cell apoptosis, and promoted chemoresistance in
ovarian cancer cells.
MiR-1307 promoted the development the chemoresistance
of ovarian cancer by targeting ING5 in vitro
The results described above pointed out a possibility
that miR-1307 promoted ovarian cancer cells progres-
sion by down-regulating ING5. To further demonstrate
this, we reversed the cell apoptosis and chemoresistance
abilities by adding ING5 siRNA following the loss of
miR-1307 at the same time (Fig. 5). As shown in Fig. 5a,
the miR-1307 expression was decreased in the ASO-
1307 following the loss of miR-1307 compared to the
ASO con group in A2780 or SKOV3 cells (P < 0.05, re-
spectively). And the decreased miR-1307 expression was
not statistically different between the ING5 siRNA +
miR-1307 ASO group or in the siRNA con +miR-1307
ASO group following the loss of miR-1307 in A2780 or
SKOV3 cells (P > 0.05, respectively). The results indi-
cated that the loss of miR-1307 was not increased by
adding ING5 siRNA, which could not have the effect on
miR-1307. Moreover, as shown in Fig. 5b, the ING5 ex-
pression was increased following the loss of miR-1307 in
Fig. 4 Influence of ING5 on the biological behaviors of ovarian cancer cell lines. a ING5 siRNA was used to reduce the expression of protein ING5
in A2780 and SKOV3 cells by using western blot. The expression of ING5 protein in A2780 or SKOV3 cells was reduced in the ING5 siRNA group
compared to the siRNA control group (P < 0.01, respectively). b Colony formation. Cells were cultured in 6-well plates and analyzed by colony
formation assay. After 10 days, cells were stained, photographed (left) and counted (right). The results of colony formation assay or annexin V-FITC
immunofluorescence assay showed that capacity for colony formation was significantly enhanced compared to the control in A2780 or SKOV3 cells,
respectively (P < 0.05). c The results of annexin V-FITC immunofluorescence assay. Cells were stained, photographed (up) and counted (down). The
results of annexin V-FITC immunofluorescence assay showed that significantly more cells of FITC compared with control in A2780 or SKOV3 cells
(P < 0.05, respectively). d Chemoresistance profiling of ING5 siRNA transfection and control group in the A2780 and SKOV3 cells. Diagram line
about different concentrations of drugs and inhibition rate, and IC50 difference between ING5 siRNA transfection and control group in the
A2780 and SKOV3 cells. The results of IC50 showed that significantly bigger IC50 compared with control in A2780 or SKOV3 cells (P < 0.05,
respectively). Results are representative of at least three separate experiments. Data are expressed as the mean ± standard deviation. Data from
three experimental determinations and bars indicate the SD (*P < 0.05, **P < 0.01)
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the ASO-1307 or in the siRNA con + miR-1307 ASO
group (P < 0.05, respectively), but the ING5 expres-
sion was not increased by adding ING5 siRNA
following the loss of miR-1307 in A2780 or SKOV3
cells (P < 0.05, respectively). The results indicated
that miR-1307 directly targeted ING5 in ovarian can-
cer cells. Moreover, the results of annexin V-FITC
immunofluorescence assay or IC50 showed that the
apoptosis rate or the chemoresistence was increased
or decreased following the loss of miR-1307 in the
ASO-1307 or in the siRNA con + miR-1307 ASO
group in A2780 or SKOV3 cells (P < 0.05, respect-
ively, Fig. 5c and d), but the increased cells apoptosis
rate or the decreased chemoresistance following the
loss of miR-1307 could be reversed by the down-
regulation of ING5 in A2780 or SKOV3 cells (P <
0.05, respectively, Fig. 5c and D). In summary, these
results suggested that miR-1307 could promote the
chemoresistance development of ovarian cancer by
targeting ING5 in vitro.
Inhibiting effect of miR-1307 ASO and/or taxol by increas-
ing the ING5 expression against ovarian cancer in vivo
To validate the inhibiting effect of miR-1307 ASO and/
or Taxol and to determine whether miR-1307 regulate
ING5 expression in vivo, we injected A2780 cells sub-
cutaneously into the right flank of nude mice. The
results were as follows: compared to the MOCK group,
the average tumor volume in Taxol group was de-
creased significantly (P < 0.01, Fig. 6a and b). And com-
pared to the ASO con group, the average tumor
volume in miR-1307 ASO and miR-1307 ASO + Taxol
group was decreased significantly (P < 0.05 and P < 0.01,
respectively, Fig. 6a and b). Besides, compared to the
Taxol group, the average tumor volume in miR-1307
ASO + Taxol group was decreased significantly (P < 0.05,
Fig. 6a and b). In addition, we evaluated the ING5 expres-
sion in the mice tumors by western blot, and the results
suggested that expression of ING5 was increased as a re-
sult of miR-1307 ASO and/or Taxol (P < 0.01, P < 0.05 and
P < 0.01, respectively, Fig. 6c). Moreover, compared to the
Fig. 5 The changed apoptosis or chemoresistance following miR-1307 loss was rescued by ING5 down-regulation. a The miR-1307 expression by
using QRT-PCR in A2780 or SKOV3 cells in the differently treated groups: The miR-1307 expression was decreased in the ASO-1307 following the
loss of miR-1307 compared to the ASO con group (P < 0.05, respectively). Besides, the decreased miR-1307 expression was not statistically different
between the ING5 siRNA +miR-1307 ASO group or in the siRNA con +miR-1307 ASO group following the loss of miR-1307 in A2780 or SKOV3
cells (P > 0.05, respectively). b The ING5 protein by using western blot in A2780 and SKOV3 cells in the differently treated groups: The ING5
expression was increased in the ASO-1307 or in the siRNA con +miR-1307 ASO group following the loss of miR-1307 in A2780 or SKOV3 cells
(P < 0.05, respectively). Meanwhile, the increased ING5 expression was not increased by adding ING5 siRNA following the loss of miR-1307 in
A2780 or SKOV3 cells (P < 0.05, respectively). c The results of apoptosis rate in the different groups in A2780 or SKOV3 cells: The results of
annexin V-FITC immunofluorescence assay showed that the apoptosis rate increased in the ASO-1307 or in the siRNA con + miR-1307 ASO
group following the loss of miR-1307 in A2780 or SKOV3 cells (P < 0.05, respectively). However, the increased cells apoptosis rate following
the loss of miR-1307 could be rescued (not increased) by down-regulation of ING5 in A2780 or SKOV3 cells (P < 0.05, respectively). d The
results of chemoresistance profiling in the different groups in A2780 and SKOV3 cells: The chemoresistance was decreased in the ASO-1307
or in the siRNA con + miR-1307 ASO group following the loss of miR-1307 (P < 0.01, respectively). However, the decreased chemoresistance
following the loss of miR-1307 could be rescued (not increased) by down-regulation of ING5 in A2780 or SKOV3 cells (P < 0.05,
respectively). (*P < 0.05)
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Taxol group, the expression of ING5 in miR-1307 ASO +
Taxol group was increased (Fig. 6c). Treatment with miR-
1307 ASO and/or Taxol resulted in no significant differ-
ence in the body weight of treated mice, none of the tested
mice manifested signs of other adverse effects as specified
in the method section, and no toxicity on the blood count
or hepatic and renal function was observed (data not
shown). These results indicated the anti-tumor effect and
safety of miR-1307 ASO and/or Taxol in vivo. To sum up,
these results suggested that miR-1307 could promote the
development the chemoresistance of ovarian cancer by
targeting ING5 in vivo.
Discussion
MiRNAs play important roles in almost all tumor cellu-
lar processes [2, 5–12], which either promote carcino-
genesis or suppress tumor development in ovarian
cancer [2, 8–12]. Particularly, many miRNAs including
miR-1307 have been linked to chemo-resistance to
many kinds of chemotherapy drugs in ovarian cancer
[2, 4, 7–9, 13–16]. Recently, miR-1307 was found to be
up-regulated in a variety of cancers, such as breast can-
cer, liver cancer, colorectal tumor and ovarian cancer
[7, 21–24]. For example, miR-1307-3p was found to be
useful for detecting breast cancer in the early stage
[21]. And methylated miR-1307 was identified in sub-
jects who went on to develop breast cancer [22]. MiR-
1307 in chronic hepatitis C was identified in a recent re-
port [23]. Even a report has indicated that rs7911488 C-
allelic pre-miR-1307 binds to MBNL1 and infers with
Dicer processing, and then leads to the decreased miR-
1307 and increased Bcl-2 expression, thus representing an
important process in the initiation of colorectal cancer
[24]. Nevertheless, up to now, we have found only one re-
port about the correlation between miR-1307 and the
ovarian cancer chemoresistance, which indicated that
miR-1307 was associated with the chemoresistance in
ovarian cancer [7]. In our article, to demonstrate the
function of miR-1307 in chemoresistance and to ex-
plore its chemoresistance mechanism, we firstly showed
that miR-1307 was over-expressed in chemoresistant
ovarian cancer cell line A2780/Taxol, which was con-
sistent with the literature report [7]. And we also found
that over-expression or loss of miR-1307 promoted or
inhabited chemoresistance in ovarian cancer cells. Be-
sides, to explain the chemoresistance caused by miR-
1307, a preliminary analysis was needed, and we found
that over-expression of miR-1307 promoted prolifera-
tion and inhibited apoptosis. Moreover, we confirmed
that the inhibitor of growth 5 (ING5) as a functional
target of miR-1307 in ovarian cancer cells. Thus, our
discovery demonstrated that miR-1307 might be a tu-
morous promoter in ovarian cancer cells, and abnormal
alteration of miR-1307-ING5 interaction might contrib-
ute to the chemoresistant in ovarian cancer.
Fig. 6 Inhibiting effect of miR-1307 ASO and Taxol by increasing ING5 in vivo. a and b The mice tumors volume in different groups. After 29 days
of treatment, the miR-1307 ASO and/or Taxol therapy decreased the tumors volume compared to the MOCK group, and compared to the ASO
con group, the average tumor volume in miR-1307 ASO and miR-1307 ASO + Taxol group was decreased significantly (P < 0.05 and P < 0.01,
respectively). Besides, compared to the Taxol group, the average tumor volume in miR-1307 ASO + Taxol group was decreased significantly
(P < 0.05). c Western Blot results of ING5 expression in different groups. ING5 expression was increased in the miR-1307 ASO and/or Taxol
treated group in ovarian cancer cells injected tumor xenografts in nude mice, and its expression was higher in the miR-1307 ASO + Taxol
treated group than that in the miR-1307 ASO treated group (P < 0.01). Results are representative of at least three separate experiments.
Data are expressed as the mean ± standard deviation. Data from three experimental determinations and bars indicate the SD (*P < 0.05, **P < 0.01)
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It is well known that most microRNAs regulate target
mRNAs by binding to the 3’ UTR of target genes in a
post-transcriptional manner [18, 19]. Therefore, establish-
ing the interrelationship of miRNA and its target genes
helps to better understand the molecular mechanism and
provide potential therapeutic targets for the clinical
treatment of cancers. Although the anti-apoptosis protein
Bcl-2, which was a direct target of miR-1307, had been
reported to be over-expressed in colorectal cancer [24],
we found that ING5 was a target gene of miR-1307 by
means of chip analysis and Target Scan software. Mean-
while, the direct targeting was further supported through
luciferase reporter assay. As a result, these data suggested
that the regulation mechanism of miR-1307 might vary in
different kinds of cancers. To confirm the hypothesis that
miR-1307 promoted ovarian cancer cell chemoresistance
by targeting the ING5 expression, a preliminary analysis
was performed, and the regulatory mechanism of miR-
1307 and downstream gene ING5 was explored. Recently,
a report suggested that miR-193a-3p-regulated ING5 gene
activated the DNA damage response pathway and inhib-
ited multi-chemoresistance in bladder cancer [18]. Differ-
ent from the result owing to the different types of cancer,
our results indicated ING5 was targeted by miR-1307, yet
we could also use the similar method to prove their cor-
relation [18, 19]. As shown in the present study, we could
see the inhibiting effect of miR-1307 ASO by increasing
the ING5 expression against chemoresistant ovarian
cancer in vitro. Of course, the similar inhibiting effect
was demonstrated in vivo. However, it was also needed
to demonstrate the effect in other types of animal
models before the clinical trial. To further explore the
mechanism, we analyzed the protein expressions fol-
lowing different miR-1307 treatment in various kinds of
ovarian cancer cells, and the results indicated the
downstream gene ING5 of miR-1307 in vitro. Further-
more, the up-regulated ability of cell apoptosis and
down-regulated ability of chemoresistance following
the loss of miR-1307 was rescued by adding ING5
siRNA in vitro. The methods by analyzing the mechan-
ism were similar with the recent reports [18, 19], and
our results indicated that miR-1307 could promote
ovarian cancer chemoresistance by targeting ING5.
ING5, one of the ING family genes and as a transcrip-
tional co-activator, has been demonstrated to play import-
ant roles in the development of tumor [18, 25–34]. Some
studies reported that the decreased ING5 protein and its
cytoplasmic translocation were observed in many tumors,
including bladder cancer [18], lung cancer [25, 27], oral
squamous cell carcinoma [28, 30], head and neck squa-
mous cell carcinoma [31], colorectal [32], pancreatic can-
cer [29], gastric carcinoma [26, 33] and ameloblastoma
[34]. In addition, it was reported that ING5 could affect
adhesion, migration, invasion, proliferation and apoptosis
of tumor cells [18, 25–34]. Bax and GADD45 were ING5
target apoptotic genes [35, 36]. The anti-proliferative ef-
fect of ING5 depended on its interaction with INCA1
[37]. It was worth noting that ING5-mediated chemoresis-
tance was closely related to their apoptotic resistance, Akt
activation, and the over-expression of chemoresistance-
related genes [18, 26, 30]. For the inhibiting effect on
epithelial-mesenchymal transition (EMT), ING5 inhibited
lung cancer aggressiveness [27], and ING5 suppressed
PI3K/Akt in breast cancer [36]. In spite of these the cor-
relation between ING5 and ovarian cancer still remained
unclear. Various studies reported that ING5 expression
was down-regulated or ING5 was a negative regulator of
chemoresistance in many kinds of tumors [18, 25–34].
Consistent with these results, we demonstrated that ING5
inhibited cell proliferation, promoted cell apoptosis and
inhabited chemoresistance in ovarian cancer.
Chemotherapy is a double-edged sword, which leads
to the treatment and the chemoresistance for tumor.
This provides a theoretical basis for the therapy, which
needs chemotherapy combined with the inhibition of
miR-1307. Even so, future studies should also determine
the ING5 feedback effect (the pathways associated with
ING5 in the above) on miR-1307 during the chemoresis-
tance in ovarian cancer cells, and the above mechanism
should be further investigated in various kinds of ovarian
cancer cells.
Conclusions
In conclusion, our data suggested that miR-1307 could
promote ovarian cancer chemoresistance by targeting
the ING5 expression and miR-1307 might serve as a
therapeutic target for ovarian cancer.
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